AbCellera Biologics Inc., headquartered in Vancouver, Canada, is a pioneering biotechnology company that focuses on the discovery and development of monoclonal antibodies. Founded in 2012, AbCellera has rapidly established itself as a leader in the biopharmaceutical industry, leveraging its innovative antibody discovery platform to accelerate the development of therapeutics. The company’s unique technology integrates advanced machine learning and high-throughput screening, enabling the rapid identification of antibodies from natural immune responses. Notable achievements include collaborations with major pharmaceutical companies and a significant role in the development of COVID-19 treatments. With a strong market position, AbCellera continues to drive advancements in antibody therapeutics, making substantial contributions to the field of immunology and drug development.
How does AbCellera's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
AbCellera's score of 28 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
AbCellera, headquartered in Canada, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges available at this time. The company does not inherit emissions data from a parent organisation, and there are no cascading initiatives from other corporate entities. As such, AbCellera's climate commitments and strategies remain unspecified, leaving a gap in their environmental impact profile.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
AbCellera has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
